{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:26:08Z","timestamp":1790429168560,"version":"4.1.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"French National Agency for Research on AIDS and Viral Hepatitis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Dolutegravir is a widespread integrase strand-transfer inhibitor (INSTI) recommended for treatment of primary HIV infection (PHI). PHI is a high-risk stage for sexual transmission because of the high viral load in semen. Yet dolutegravir concentrations in semen are lower than in blood during chronic treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare the kinetics of HIV-RNA and total HIV-DNA in the genital compartment in subjects receiving either tenofovir\/emtricitabine\/dolutegravir or tenofovir\/emtricitabine\/darunavir\/cobicistat as a first-line combined ART (cART) at the time of PHI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Eighteen subjects receiving tenofovir\/emtricitabine\/dolutegravir and 19 receiving tenofovir\/emtricitabine\/darunavir\/cobicistat enrolled in the ANRS169 OPTIPRIM-2 trial participated in the genital substudy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between week (W) 0 and W2 HIV-RNA in seminal plasma (SP) decreased by 1\u2009log10 copies\/mL. Undetectable SP HIV-RNA was achieved in similar proportions between the two regimens at each timepoint. Overall, eight patients still presented detectable HIV-RNA or HIV-DNA in semen at W48; 15.4% and 28.6% presented detectable HIV-RNA and 9.1% and 14.3% presented detectable HIV-DNA in dolutegravir- and darunavir-based cART groups, respectively, with no significant difference.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>For the first time, to the best of our knowledge, we showed that a dolutegravir-based regimen initiated as soon as PHI reduces HIV-RNA and HIV-DNA with no difference compared with a control group receiving a darunavir-based regimen. Although the viral purge in semen seems longer after treatment in PHI than CHI, due to high viral loads, early dolutegravir-based treatment initiation permits a major decay of both viral particles and infected cells in semen, efficiently reducing the high risk of transmission during PHI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab427","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T19:13:59Z","timestamp":1635448439000},"page":"735-739","source":"Crossref","is-referenced-by-count":6,"title":["HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-2967","authenticated-orcid":false,"given":"Alice-Andr\u00e9e","family":"Mariaggi","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Paris, Facult\u00e9 de M\u00e9decine, Paris, France"},{"name":"INSERM U1016, CNRS UMR8104, Institut Cochin, Paris, France"},{"name":"AP-HP, Laboratoire de Virologie, CHU Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bauer","sequence":"additional","affiliation":[{"name":"INSERM SC10, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Charre","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Facult\u00e9 de M\u00e9decine, Paris, France"},{"name":"INSERM U1016, CNRS UMR8104, Institut Cochin, Paris, France"},{"name":"AP-HP, Laboratoire de Virologie, CHU Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Gardiennet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Facult\u00e9 de M\u00e9decine, Paris, France"},{"name":"INSERM U1016, CNRS UMR8104, Institut Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Meiffredy","sequence":"additional","affiliation":[{"name":"INSERM SC10, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Ajana","sequence":"additional","affiliation":[{"name":"CH Tourcoing, Service de Maladies Infectieuses, Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Saint Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France"},{"name":"Sorbonne Universit\u00e9, Facult\u00e9 de M\u00e9decine, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Pialoux","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Facult\u00e9 de M\u00e9decine, Paris, France"},{"name":"AP-HP, H\u00f4pital Tenon, Service de Maladies Infectieuses et Tropicales, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Cua","sequence":"additional","affiliation":[{"name":"CHU de Nice l'Archet, Service de Maladies Infectieuses et Tropicales, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rouzioux","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Facult\u00e9 de M\u00e9decine, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Meyer","sequence":"additional","affiliation":[{"name":"INSERM SC10, Villejuif, France"},{"name":"INSERM CESP U1018, Universit\u00e9 Paris Saclay, H\u00f4pital Bic\u00eatre, Assistance Publique-H\u00f4pitaux de Paris (APHP), Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Cheret","sequence":"additional","affiliation":[{"name":"INSERM U1016, CNRS UMR8104, Institut Cochin, Paris, France"},{"name":"AP-HP, Service de M\u00e9decine Interne et d'Immunologie Clinique, H\u00f4pital Bic\u00eatre, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Avettand-Fenoel","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Facult\u00e9 de M\u00e9decine, Paris, France"},{"name":"INSERM U1016, CNRS UMR8104, Institut Cochin, Paris, France"},{"name":"AP-HP, Laboratoire de Microbiologie clinique, H\u00f4pital Necker-Enfants Malades, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"2022022312593270400_dkab427-B1","author":"UNAIDS","year":"2016"},{"key":"2022022312593270400_dkab427-B2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/590501","article-title":"HIV-1 transmission, by stage of infection","volume":"198","author":"Hollingsworth","year":"2008","journal-title":"J Infect Dis"},{"key":"2022022312593270400_dkab427-B3","doi-asserted-by":"crossref","first-page":"77ra29","DOI":"10.1126\/scitranslmed.3001888","article-title":"Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission","volume":"3","author":"Baeten","year":"2011","journal-title":"Sci Transl Med"},{"key":"2022022312593270400_dkab427-B4","author":"WHO","year":"2021"},{"key":"2022022312593270400_dkab427-B5","author":"European AIDS Clinical Society","year":"2020"},{"key":"2022022312593270400_dkab427-B6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31829ed7a4","article-title":"Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing","volume":"64","author":"Greener","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022022312593270400_dkab427-B7","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/infdis\/jiw406","article-title":"HIV-1-RNA decay and dolutegravir concentrations in semen of patients starting a first antiretroviral regimen","volume":"214","author":"Imaz","year":"2016","journal-title":"J Infect Dis"},{"key":"2022022312593270400_dkab427-B8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jcv.2018.11.002","article-title":"HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen","volume":"109","author":"Fabrizio","year":"2018","journal-title":"J Clin Virol"},{"key":"2022022312593270400_dkab427-B9","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/jac\/dkaa035","article-title":"Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial)","volume":"75","author":"Charpentier","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022022312593270400_dkab427-B10","article-title":"OPTIPRIM2 ANRS trial comparing dolutegravir vs darunavir in acute HIV-1 infection","author":"Cheret"},{"key":"2022022312593270400_dkab427-B11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jmv.21390","article-title":"LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01)","volume":"81","author":"Avettand-Fenoel","year":"2009","journal-title":"J Med Virol"},{"key":"2022022312593270400_dkab427-B12","doi-asserted-by":"crossref","first-page":"e25221","DOI":"10.1002\/jia2.25221","article-title":"Dynamics in HIV-DNA levels over time in HIV controllers","volume":"22","author":"Avettand-Fenoel","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"2022022312593270400_dkab427-B13","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/00002030-200309050-00005","article-title":"Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection","volume":"17","author":"Fiebig","year":"2003","journal-title":"AIDS"},{"key":"2022022312593270400_dkab427-B14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/OLQ.0b013e318141fe9b","article-title":"Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings","volume":"35","author":"Kalichman","year":"2008","journal-title":"Sex Transm Dis"},{"key":"2022022312593270400_dkab427-B15","doi-asserted-by":"crossref","first-page":"e0180191","DOI":"10.1371\/journal.pone.0180191","article-title":"Impact of early cART on HIV blood and semen compartments at the time of primary infection","volume":"12","author":"Cheret","year":"2017","journal-title":"PLoS One"},{"key":"2022022312593270400_dkab427-B16","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1089\/aid.2008.0014","article-title":"HIV dynamics in seminal plasma during primary HIV infection","volume":"24","author":"Stekler","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022022312593270400_dkab427-B17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/jac\/dkz482","article-title":"Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir\/abacavir\/lamivudine","volume":"75","author":"Fernandez-Gonzalez","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022022312593270400_dkab427-B18","article-title":"HIV-1-RNA kinetics in blood plasma and in seminal plasma of men starting a dolutegravir-based triple-combination regimen at the time of primary HIV-1 infection","author":"Ghosn","year":"2021","journal-title":"J Infect Dis"},{"key":"2022022312593270400_dkab427-B19","doi-asserted-by":"crossref","first-page":"S606","DOI":"10.1093\/infdis\/jiu538","article-title":"Cell-associated HIV mucosal transmission: the neglected pathway","volume":"210 Suppl 3","author":"Anderson","year":"2014","journal-title":"J Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/3\/735\/42587170\/dkab427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/3\/735\/42587170\/dkab427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T15:23:50Z","timestamp":1645629830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/3\/735\/6433478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,11,23]]},"published-print":{"date-parts":[[2022,2,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab427","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,2]]},"published":{"date-parts":[[2021,11,23]]}}}